Clinical Trial Update: A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating BI 1015550 for progressive fibrosing interstitial lung diseases has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Progressive Fibrosing Interstitial Lung Disease

Drugs mentioned

• BI-1015550 (BI-1015550)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lung Diseases, Interstitial | Phase 3 | Status: COMPLETED | Results posted: 2026-01-09